- Home
- AYTU vs RDHL Comparison
AYTU vs RDHL Comparison
Compare AYTU & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AYTU
- RDHL
- Stock Information
- Founded
- AYTU N/A
- RDHL 2009
- Country
- AYTU United States
- RDHL Israel
- Employees
- AYTU N/A
- RDHL N/A
- Industry
- AYTU Biotechnology: Pharmaceutical Preparations
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- AYTU Health Care
- RDHL Health Care
- Exchange
- AYTU Nasdaq
- RDHL Nasdaq
- Market Cap
- AYTU 9.6M
- RDHL 3.8M
- IPO Year
- AYTU N/A
- RDHL N/A
- Fundamental
- Price
- AYTU $2.39
- RDHL $2.03
- Analyst Decision
- AYTU Strong Buy
- RDHL
- Analyst Count
- AYTU 2
- RDHL 0
- Target Price
- AYTU $10.00
- RDHL N/A
- AVG Volume (30 Days)
- AYTU 669.1K
- RDHL 19.2K
- Earning Date
- AYTU 05-14-2025
- RDHL 04-10-2025
- Dividend Yield
- AYTU N/A
- RDHL N/A
- EPS Growth
- AYTU N/A
- RDHL N/A
- EPS
- AYTU N/A
- RDHL N/A
- Revenue
- AYTU $81,659,000.00
- RDHL $8,042,999.00
- Revenue This Year
- AYTU N/A
- RDHL $381.91
- Revenue Next Year
- AYTU $8.68
- RDHL N/A
- P/E Ratio
- AYTU $13.06
- RDHL N/A
- Revenue Growth
- AYTU 0.41
- RDHL 23.17
- 52 Week Low
- AYTU $0.95
- RDHL $1.71
- 52 Week High
- AYTU $2.96
- RDHL $20.28
- Technical
- Relative Strength Index (RSI)
- AYTU 69.98
- RDHL 57.04
- Support Level
- AYTU $2.04
- RDHL $1.75
- Resistance Level
- AYTU $2.40
- RDHL $2.08
- Average True Range (ATR)
- AYTU 0.13
- RDHL 0.09
- MACD
- AYTU 0.02
- RDHL 0.03
- Stochastic Oscillator
- AYTU 92.00
- RDHL 85.16
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.